Example of American Journal of Hematology format
Recent searches

Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format Example of American Journal of Hematology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access
recommended Recommended

American Journal of Hematology — Template for authors

Publisher: Wiley
Categories Rank Trend in last 3 yrs
Hematology #11 of 123 up up by 1 rank
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 732 Published Papers | 7513 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 15/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access

Springer

Quality:  
High
CiteRatio: 4.6
SJR: 1.06
SNIP: 1.301
open access Open Access

Springer

Quality:  
High
CiteRatio: 6.3
SJR: 1.037
SNIP: 0.989
open access Open Access

Elsevier

Quality:  
High
CiteRatio: 7.2
SJR: 1.638
SNIP: 0.997

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

6.973

14% from 2018

Impact factor for American Journal of Hematology from 2016 - 2019
Year Value
2019 6.973
2018 6.137
2017 5.303
2016 5.275
graph view Graph view
table view Table view

10.3

12% from 2019

CiteRatio for American Journal of Hematology from 2016 - 2020
Year Value
2020 10.3
2019 9.2
2018 8.7
2017 8.2
2016 7.4
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 14% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 12% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

2.456

2% from 2019

SJR for American Journal of Hematology from 2016 - 2020
Year Value
2020 2.456
2019 2.416
2018 2.164
2017 2.092
2016 1.936
graph view Graph view
table view Table view

2.229

12% from 2019

SNIP for American Journal of Hematology from 2016 - 2020
Year Value
2020 2.229
2019 1.988
2018 1.688
2017 1.625
2016 1.583
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 2% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 12% in last years.
  • This journal’s SNIP is in the top 10 percentile category.
American Journal of Hematology

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Wiley

American Journal of Hematology

The American Journal of Hematology provides broad coverage of experimental and clinical features of blood diseases in humans and in animal models of human disease. The journal publishes original contributions in non-malignant and malignant hematological diseases including clin...... Read More

Hematology

Medicine

i
Last updated on
15 Jun 2020
i
ISSN
0361-8609
i
Impact Factor
High - 1.538
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Yellow faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
apa
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Blonder GE, Tinkham M, Klapwijk TM. Transition from metallic to tunneling regimes in superconducting micro-constrictions: Excess current, charge imbalance, and supercurrent conversion. Phys Rev B. 1982;25(7):4515–4532.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1002/AJH.25829
Hematological findings and complications of COVID-19.

Abstract:

COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the... COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID-19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted. read more read less

Topics:

Blood coagulation test (58%)58% related to the paper, Disseminated intravascular coagulation (55%)55% related to the paper, Low molecular weight heparin (53%)53% related to the paper, Hemostasis (53%)53% related to the paper, Hematology (52%)52% related to the paper
1,321 Citations
open accessOpen access Journal Article DOI: 10.1002/AJH.20381
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

Abstract:

We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light-chain amyloidosis (AL). A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis. Inst... We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light-chain amyloidosis (AL). A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis. Institutional criteria were submitted from each, and a consensus was developed defining each organ involved and the criteria for response. Specific criteria have been developed with agreed on definitions of organ and hematologic response as a result of discussions at the 10th International Symposium on Amyloid and Amyloidosis held in Tours, France, April 2004. These criteria now form the working definition of involvement and response for the purposes of future data collection and reporting. We report criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light-chain AL. read more read less

Topics:

Cardiac amyloidosis (59%)59% related to the paper, Renal amyloidosis (58%)58% related to the paper, AL amyloidosis (58%)58% related to the paper, Primary systemic amyloidosis (56%)56% related to the paper, Amyloidosis (55%)55% related to the paper
View PDF
1,139 Citations
Journal Article DOI: 10.1002/AJH.10062
Autoimmune hemolytic anemia
Bradley Gehrs1, Richard C. Friedberg2

Abstract:

Red blood cell (RBC) autoantibodies are a relatively uncommon cause of anemia. However, autoimmune hemolytic anemia (AIHA) must be considered in the differential diagnosis of hemolytic anemias, especially if the patient has a concomitant lymphoproliferative disorder, autoimmune disease, or viral or mycoplasmal infection. Clas... Red blood cell (RBC) autoantibodies are a relatively uncommon cause of anemia. However, autoimmune hemolytic anemia (AIHA) must be considered in the differential diagnosis of hemolytic anemias, especially if the patient has a concomitant lymphoproliferative disorder, autoimmune disease, or viral or mycoplasmal infection. Classifications of AIHA include warm AIHA, cold agglutinin syndrome, paroxysmal cold hemoglobinuria, mixed-type AIHA, and drug-induced AIHA. Characteristics of the autoantibodies are responsible for the various clinical entities. As a result, diagnosis is based on the clinical presentation and a serologic work-up. For each classification of AIHA, this review discusses the demographics, etiology, clinical presentation, laboratory evaluation, and treatment options. read more read less

Topics:

Autoimmune hemolytic anemia (68%)68% related to the paper, Cold agglutinin disease (62%)62% related to the paper, Paroxysmal cold hemoglobinuria (56%)56% related to the paper, Hemolytic anemia (56%)56% related to the paper
View PDF
573 Citations
open accessOpen access Journal Article DOI: 10.1002/AJH.25774
Hematologic parameters in patients with COVID-19 infection.

Abstract:

To the Editor: A cluster of unexplained pneumonia cases was reported by the Peopleʼs Republic of China to the World Health Organization (WHO) on 31 December, 2019. The etiology for this outbreak was a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was responsible for the Corona Vir... To the Editor: A cluster of unexplained pneumonia cases was reported by the Peopleʼs Republic of China to the World Health Organization (WHO) on 31 December, 2019. The etiology for this outbreak was a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was responsible for the Corona Virus Disease 2019 (COVID-19). Singapore confirmed its first imported case on 23 January 2020 and local transmission was detected on 4 February, 2020. As of 28 February, 2020, Singapore had 96 confirmed cases of COVID-19 infection. SARS-CoV-2 was confirmed by real time reverse transcriptase-polymerase chain reaction (RT-PCR), performed on respiratory samples of these patients. A majority of 69 out of these 96 patients were treated at the National Centre for Infectious Diseases (NCID). We herein present a detailed analysis of the hematological parameters of the COVID-19 patients at the NCID (see Table 1). Of the 69 patients that had been admitted to the NCID, 26 patients were still hospitalized, and 43 patients had been discharged as of 28 February 2020. Also, 67 patients had at least one complete blood count (CBC) performed during inpatient stay; 65 patients had CBC performed on day of admission. We analyzed the hematological indices of all COVID-19 infected patients from day 1 of admission until 28 February 2020. We obtained data from the Laboratory Information System (LIS) exclusively which provided information on the age, gender, ethnicity and location of each patient. We divided the patients into two groups; ICU and non-ICU patients. Additionally, flow cytometry on lymphocyte subsets was performed from 24 to 28 February 2020, on a subgroup of nine COVID-19 patients; five ICU patients and four non-ICU patients (with six normal individual blood samples as controls). Immunophenotyping was performed using a Becton Dickinson FACSCanto II Flow analyzer. Most patients were of Chinese ethnicity (89.5%), while the minority were ofMalay (4.5%), Indian (1.5%) and other ethnicities (4.5%). Just 9 out of the 67 (13.4%) patients required ICU care. Notably, ICU patients were about a decade older than the non-ICU patients; the median age of ICU patients was 54 years old while the median age of non-ICU patients was 42 years old (P = .02). On admission, leukopenia was observed in 19 patients (29.2%) with only one patient presenting with severe leukopenia (WBC < 2 × 10/L). Lymphopenia featured in 24 patients (36.9%) with 19 having moderate lymphopenia (absolute lymphocyte count [ALC] 0.5-1 × 10/L), and five with severe lymphopenia (ALC < 0.5 × 10/L). Most patients had normal platelet counts, with 13 patients (20.0%) having mild thrombocytopenia (platelet count 100-150 × 10/L). Peripheral blood film review showed that a higher number of patients (69%) who were lymphopenic had the presence of a few reactive lymphocytes, of which a subset appeared lymphoplasmacytoid. This contrasts with the severe acute respiratory syndrome (SARS) outbreak in 2003 where reactive lymphocytes were not observed in a study on Haematologic parameters in SARS in Singapore and only in 15.2% of cases in a similar Hong Kong study. Our analysis revealed that on admission, most patients had a normal CBC (normal Hb, WBC and platelet count) and lactate dehydrogenase (LDH). And, no patient presented with moderate or severe thrombocytopenia that is frequently observed in other viral illnesses such as dengue fever which is endemic in our region. However, 28% of all patients presented with lymphopenia (ALC < 1 × 10/L). This number is significantly smaller compared to 63% of patients in Wuhan, China, and 42% of patients outside of Wuhan who presented with lymphopenia. This disparity in numbers may in part be reflective of the extent of epidemiological data availablewithin the surveillance pyramid in those regions. Those requiring ICU care had a lower ALC and higher LDH. These were findings also reported by Huang et al on the characteristics of COVID-19 patients inWuhan, China. Lymphopenia has beenwell described in retrospective analysis of patients in Hong Kong and Singapore afflicted with SARS-CoV in 2003, and was associated with adverse outcomes and ICU stay. Lymphopenia featured prominently in our COVID-19 ICU groupwith amedian nadir ALC of 0.4× 10/L, compared to 1.2 × 10/L in the non-ICU group. Monitoring of such hematologic parameters may help to identify patients whomay need ICU care. An ALC approaching severe lymphopenia of <0.6 × 10/L may possibly be considered as one of the indicators for early admission for supportive care in the ICU. Between the ICU (n = 9) and non-ICU (n = 58) patients, using Fisherʼs exact tests, we found that admission ALC and LDH stood out as discriminating laboratory indices with a P value of <.001 and .005 respectively. The ICU patients in general presented with more profound lymphopenia with seven out of nine being lymphopenic; four of whom had severe lymphopenia. Note, LDH was performed for 4 out of the 9 ICU patients on admission, and all four cases had a raised LDH with a median value of 1684 U/L (reference range 270-550 U/L). Comparatively non-ICU patients tend to present with a normal LDH, median value 401 U/L; with only five out of 26 non-ICU patients presenting with a Received: 2 March 2020 Revised: 3 March 2020 Accepted: 3 March 2020 read more read less
View PDF
545 Citations
open accessOpen access Journal Article DOI: 10.1002/AJH.23599
TEG and ROTEM: Technology and clinical applications
David Whiting1, James A. DiNardo1

Abstract:

Initially described in 1948 by Hertert thromboelastography (TEG) provides a real-time assessment of viscoelastic clot strength in whole blood. Rotational thromboelastometry (ROTEM) evolved from TEG technology and both devices generate output by transducing changes in the viscoelastic strength of a small sample of clotting blo... Initially described in 1948 by Hertert thromboelastography (TEG) provides a real-time assessment of viscoelastic clot strength in whole blood. Rotational thromboelastometry (ROTEM) evolved from TEG technology and both devices generate output by transducing changes in the viscoelastic strength of a small sample of clotting blood (300 µl) to which a constant rotational force is applied. These point of care devices allow visual assessment of blood coagulation from clot formation, through propagation, and stabilization, until clot dissolution. Computer analysis of the output allows sophisticated clot formation/dissolution kinetics and clot strength data to be generated. Activation of clot formation can be initiated with both intrinsic (kaolin, ellagic acid) and extrinsic (tissue factor) activators. In addition, the independent contributions of platelets and fibrinogen to final clot strength can be assessed using added platelet inhibitors (abciximab and cytochalasin D). Increasingly, ROTEM and TEG analysis is being incorporated in vertical algorithms to diagnose and treat bleeding in high-risk populations such as those undergoing cardiac surgery or suffering from blunt trauma. Some evidence suggests these algorithms might reduce transfusions, but further study is needed to assess patient outcomes. read more read less

Topics:

Thromboelastography (58%)58% related to the paper, Thromboelastometry (57%)57% related to the paper, Thrombelastography (53%)53% related to the paper
View PDF
474 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for American Journal of Hematology.

It automatically formats your research paper to Wiley formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

American Journal of Hematology format uses apa citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write American Journal of Hematology in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the American Journal of Hematology guidelines and auto format it.

2. Do you follow the American Journal of Hematology guidelines?

Yes, the template is compliant with the American Journal of Hematology guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in American Journal of Hematology?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the American Journal of Hematology citation style.

4. Can I use the American Journal of Hematology templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for American Journal of Hematology.

5. Can I use a manuscript in American Journal of Hematology that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper American Journal of Hematology that you can download at the end.

6. How long does it usually take you to format my papers in American Journal of Hematology?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in American Journal of Hematology.

7. Where can I find the template for the American Journal of Hematology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per American Journal of Hematology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the American Journal of Hematology's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. American Journal of Hematology an online tool or is there a desktop version?

SciSpace's American Journal of Hematology is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like American Journal of Hematology?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like American Journal of Hematology?”

11. What is the output that I would get after using American Journal of Hematology?

After writing your paper autoformatting in American Journal of Hematology, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is American Journal of Hematology's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for American Journal of Hematology?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for American Journal of Hematology. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In American Journal of Hematology?

The 5 most common citation types in order of usage for American Journal of Hematology are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the American Journal of Hematology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per American Journal of Hematology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download American Journal of Hematology in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in American Journal of Hematology Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to American Journal of Hematology formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template